AIM: @entity50664 , a long-acting @entity7236 with a good antihypertensive efficacy and tolerability in clinical use. With the aim to determine the efficacy and tolerability of this drug in usual clinical practice we performed the ELYPSE trial. METHODS: Grade 1 or 2 essential @entity101 @entity1 in whom their physicians considered to prescribe a @entity7236 were conferred to @entity50664 10 mg once daily with a 3-month follow-up; 9059 @entity1 were included (age: 63 +/- 11 years; 58% @entity1 , 60% over 60 years, 56% grade 2 @entity101 and 69% previously treated with other antihypertensive drugs). A subgroup of 1267 @entity1 (14%) who were included in the study had experienced adverse reactions with other drugs. Electronic case-report forms and a central database (Internet) were used in this trial. RESULTS: At baseline, blood pressure (BP) was 160.1 +/- 10.2/95.6 +/- 6.6 mmHg; and heart rate (HR) 77.3 +/- 9.3 beats/min. Significant reductions in both systolic and diastolic BP were attained at 1 month with slight additional decreases 2 months later. At 3 months, BP was 141.4 +/- 11.3/ 83.1 +/- 6.9 mmHg, and HR 75.2 +/- 8.2 beats/min (p < 0.001 versus baseline). At the study end. 64% of the @entity1 achieved a diastolic BP < 90 mmHg, BP control (< 140/90 mmHg) was attained in 32%. In the subgroup of @entity6 (n = 1269) an adequate BP control (< 130/85) was attained in only 16.4%. The overall incidence of adverse events was 6.5%, of which the most frequent were @entity10 (2.9%), ankle @entity4 (1.2%), flushing (1.1%) and palpitations (0.6%). Withdrawal rate was < 1%. The efficacy and tolerability in the subgroup of @entity1 included in the study due to adverse events with other drugs were similar to the whole study group. CONCLUSION: In this study @entity50664 has shown a good efficacy and tolerability in daily clinical practice. These findings are concordant with those reported in randomized controlled trials.

Antihypertensive efficacy and tolerability of XXXX in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity7236 :: ('MESH:C038806', 'Chemical') :: ['dihydropyridine'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensives', 'hypertensive'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetics'] @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema'] @entity50664 :: ('MESH:C060343', 'Chemical') :: ['Lercanidipine'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']
@entity50664 :: (MESH:C060343,Chemical) :: ['lercanidipine']
